Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in NNOX.

← Back to Free Index

NNOX

Analysis as of: 2026-10-28

Nano-X Imaging Ltd.

Nanox develops digital X-ray imaging systems and sells teleradiology, AI imaging analytics, cloud software, and health IT services for medical imaging workflows.

ai cloud healthcare medical devices software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Distressed Imaging Platform With Real Re-Rating Torque

The upside does not require category dominance. It requires survival, then proof that live sites produce recurring scans and pull through software and reading revenue at a scale the market no longer expects.

Analysis

Thesis

Nanox is a distressed but real option on turning a cleared imaging device plus workflow, teleradiology and health IT stack into a recurring community-imaging utility; if it secures runway and proves routine reimbursed scan volume, 2031 value can compound non-linearly from today’s near-cash equity base.

Last Economy Alignment

Moderately positive: cheaper AI helps remote reads, workflow orchestration and verification, but value capture only holds if Nanox owns regulated workflow and avoids sliding into commodity services.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

47.7x (from 5 most recent analyses)

Reasoning

This is a survival-plus-proof story. If Nanox clears the financing gate and turns deployed systems into active scan volume, investors can re-rate it from a going-concern problem to a small integrated imaging utility. I keep the exit framework conservative versus software because reimbursement, service delivery and hardware still matter, but the current enterprise value is so depressed that even middling execution can create venture-like upside.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

This is a sequence-risk equity. Nanox first needs financing flexibility and listing continuity, then active site conversion, then proof that scan volume pulls through hardware, reading and software revenue with acceptable economics. The attractive part of the setup is that expectations are already crushed; the dangerous part is that dilution and stalled utilization can destroy the equity before the flywheel starts.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

October 28, 2026 proxy materials formalized the November 18, 2026 vote to add 300.0 million authorized shares and approve a 1-for-20 to 1-for-50 reverse-split framework.
The new proxy disclosed 78.7 million shares outstanding as of October 28, 2026 and highlighted $53.9 million of remaining at-the-market capacity, sharpening the dilution-versus-survival trade-off.
No offsetting liquidity fix has been announced since the October 16, 2026 preliminary Q3 update, so financing remains the dominant near-term gate.

Forecast update

The upside torque improved because equity value fell closer to cash while the new proxy clarified both current share count and how central financing flexibility is to survival.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.26

They control a cleared imaging device plus the reading and workflow around it, so cheaper AI can make each installed site more useful and cheaper to run. But if cash runs out or bigger incumbents own the workflow, their software layer risks becoming just another low-value add-on.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$4.13

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research